A Multicenter, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sulbactam-Durlobactam in Hospitalized Pediatric Patients From Birth to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Acinetobacter Baumannii-calcoaceticus Complex Infection
Latest Information Update: 04 Jul 2025
At a glance
- Drugs Durlobactam/sulbactam (Primary)
- Indications Acinetobacter infections
- Focus Pharmacokinetics
- Sponsors Innoviva Specialty Therapeutics
Most Recent Events
- 26 Jun 2025 Planned initiation date changed from 30 Jul 2025 to 30 Aug 2025.
- 30 May 2025 Planned initiation date (estimated date of first participant enrollment) changed from 30 May 2025 to 30 Jul 2025.
- 01 Apr 2025 Planned initiation date (estimated date of first participant enrollment) changed from 31 Mar 2025 to 30 May 2025.